Abstract:The capsid assembly is a significant phase for the hepatitis B virus (HBV) lifespan and is an essential target for anti-HBV drug discovery and development. Herein, we used scaffold hopping, bioisosterism, and pharmacophore hybrid-based strategies to design and synthesize six series of various heterocycle derivatives (pyrazole, thiazole, pyrazine, pyrimidine, and pyridine) and screened for in vitro anti-HBV non-nucleoside activity. Drug candidate NZ-4 and AT-130 were used as lead compounds. Several compounds exhibited prominent anti-HBV activity compared to lead compound NZ-4 and positive drug Lamivudine, especially compound II-8b, showed the most prominent anti-HBV DNA replication activity (IC50 = 2.2 ± 1.1 μM). Also compounds IV-8e and VII-5b showed the best in vitro anti-HBsAg secretion (IC50 = 3.8 ± 0.7 μM, CC50 > 100 μM) and anti-HBeAg secretion (IC50 = 9.7 ± 2.8 μM, CC50 > 100 μM) respectively. Besides, II-8b can interact HBV capsid protein with good affinity constants (KD = 60.0 μM), which is equivalent to lead compound NZ-4 ((KD = 50.6 μM). The preliminary structure-activity relationships (SARs) of the newly synthesized compounds were summarized, which may help researchers to discover more potent anti-HBV agents.

Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Synthesis of Janus Type Nucleoside Analogues and Their Preliminary Bioactivity

Design, Synthesis and Primary Biological Evaluation of the Novel 2-Pyridone Derivatives As Potent Non-Nucleoside HBV Inhibitors.

Design and Synthesis of Novel Benzimidazole Derivatives As Inhibitors of Hepatitis B Virus

Design, Synthesis, Molecular Docking Studies and Anti-Hbv Activity of Phenylpropanoid Derivatives

Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Synthesis and anti-hepatitis B virus activity of a novel class of thiazolylbenzimidazole derivatives.

Synthesis and Anti-Hepatitis B Virus Activity of Novel Benzimidazole Derivatives

Synthesis and Anti-HBV Activity of Novel Dihydropyrimidine Analogs

2-Arylthio-5-iodo Pyrimidine Derivatives As Non-Nucleoside HBV Polymerase Inhibitors

Design, Synthesis and Evaluation of Pyrazole Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors

Design and Synthesis of (3-Phenylisoxazol-5-yl)methanimine Derivatives as Hepatitis B Virus Inhibitors

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Design, Diversity-Oriented Synthesis and Biological Evaluation of Novel Heterocycle Derivatives As Non-Nucleoside HBV Capsid Protein Inhibitors.

Synthesis and Biological Evaluation of Phenylpropanoid Derivatives

Design, Synthesis, and Evaluation of Novel Heteroaryldihydropyrimidine Derivatives As Non‐nucleoside Hepatitis B Virus Inhibitors by Exploring the Solvent‐exposed Region

Synthesis and Biological Evaluation of Novel Anti-Hepatitis C Virus (HCV) Agents: 2-Hydroxylphenethyl Sulfanyl-Oxopyrimidines

Discovery and Biological Evaluation of 2-((3-phenylisoxazol-5-yl) Methoxy) Benzamide Derivatives As Potent Nucleocapsid Inhibitors

Synthesis and Evaluation of 3-Phenylisoxazoline Derivatives As Non-Nucleoside Hepatitis B Virus Inhibitors